{
    "nct_id": "NCT04989504",
    "official_title": "Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: a Randomized Phase III Clinical Trial",
    "inclusion_criteria": "* Histologic confirmation of breast malignancy with TNM staging.\n* Patients must have undergone a mastectomy with or without reconstruction within the past 120 days if not receiving adjuvant therapy, or within 60 days after completion of the last dose of chemotherapy.\n* No prior radiotherapy to any portion of the planned treatment site.\n* No documented history of adhesive or tape allergy.\n* Patients must be scheduled to receive conventionally fractionated photon-based radiation. Patients planning brachytherapy within the treatment field, and patients scheduled to receive bilateral radiation or hypofractionated radiation are not eligible.\n* No active rash or pre-existing dermatitis within the treatment field.\n* No co-existing medical conditions resulting in life expectancy < 2 years.\n* No active collagen vascular diseases (i.e. lupus erythematosus, scleroderma, dermatomyositis).\n* No concomitant cytotoxic chemotherapy. Endocrine therapy and HER2 directed therapies are allowed.\n* No current inflammatory breast cancer, or gross dermal involvement at initiation of radiotherapy.\n* No previous history of organ or bone marrow transplant.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* In order to complete the mandatory patient-completed measures, participants must be able to speak and read English.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}